The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Targeting the PI3K pathway in patients who fail JAK inhibitor therapy
Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the promise of targeting the PI3K pathway in patients who fail JAK inhibitor therapy, and the potential long-term benefits of this therapeutic strategy. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie
